Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

Patent metadata

Field	Value
Publication number	US-12084498-B2
Application number	US-202117388052-A
Country	US
Kind code	B2
Filing date	Jul 29, 2021
Priority date	Feb 20, 2013
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

First claim

We claim:

1. A method of treating an peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), comprising administering to an individual suffering from said PTCL-NOS a therapeutically active amount of an antibody that binds a KIR3DL2 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and that further: i) directs ADCC toward a KIR3DL2-expressing cell, or ii) delivers a cytotoxic agent to a KIR3DL2-expressing cell.

2. The method of claim 1 , wherein the treatment comprises:
a) determining the KIR3DL2 polypeptide status of malignant cells within the individual having an PTCL-NOS, and
b) upon a determination that the individual has a KIR3DL2 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 expressed on the surface of malignant cells, administering to the individual said antibody that binds a KIR3DL2 polypeptide and that further: i) directs ADCC toward the KIR3DL2-expressing malignant cells and/or ii) delivers a cytotoxic agent to the KIR3DL2-expressing malignant cells.

3. The method of claim 1 , wherein the anti-KIR3DL2 antibody directs ADCC toward a KIR3DL2-expressing cell.

4. The method of claim 3 , wherein the antibody comprises an amino acid modification that enhances binding to a human Fcγ receptor.

5. The method of claim 3 , wherein the anti-KIR3DL2 antibody binds human KIR3DL2 but does not bind to human KIR3DL1.

6. The method of claim 1 , wherein the antibody is linked to a cytotoxic agent.

7. The method of claim 1 , wherein the anti-KIR3DL2 antibody binds human KIR3DL2 but does not bind to human KIR3DL1.

8. The method of claim 1 , wherein the KIR3DL2 antibody comprises an antibody variable region comprising:
a) a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NOs: 7, 8 or 9, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 10 or 11, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 12 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 13, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 14, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 15;
b) a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 18, 19 or 20, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 21 or 22, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 23 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 24, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 25, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 26;
c) a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 34, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 38, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 39 and a light chain variable region chain comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 40, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 41, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 42; or
d) a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 35, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 37, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 39 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 40, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 41, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 42.

9. The method of claim 8 , wherein the KIR3DL2 antibody comprises a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NOs: 7, 8 or 9, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 10 or 11, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 12 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 13, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 14, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 15.

10. The method of claim 8 , wherein the KIR3DL2 antibody comprises a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 18, 19 or 20, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 21 or 22, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 23 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 24, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 25, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 26.

11. The method of claim 8 , wherein the KIR3DL2 antibody comprises an antibody variable region comprising a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 34, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 38, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 39 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 40, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 41, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 42.

12. The method of claim 8 , wherein the KIR3DL2 antibody comprises a heavy chain variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 35, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 37, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 39 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 40, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 41, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 42.

13. A method of treating an peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), comprising administering to an individual suffering from said PTCL-NOS a therapeutically active amount of an antibody that binds a KIR3DL2 polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and that further directs ADCC toward a KIR3DL2-expressing cell, wherein the KIR3DL2 antibody comprises an antibody variable region comprising a heavy chain CDR1 (hCDR1) comprising SEQ ID NO: 35, a heavy chain CDR2 (hCDR2) comprising SEQ ID NO: 37, a heavy chain CDR3 (hCDR3) comprising SEQ ID NO: 39 and a light chain variable region comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO: 40, a light chain CDR2 (LCDR2) comprising SEQ ID NO: 41, and a light chain CDR3 (LCDR3) comprising SEQ ID NO: 42.

Assignees

• Innate Pharma

Inventors

• Bonnafous Cécile
• Sicard Hélène
• Buffet Renaud

Classifications

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• G01N2333/70503

  Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 · CPC title

• C07K16/3023

  Lung · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title

• C07K16/3061

  Blood cells · CPC title